Last month brought changes to thirty-nine (39) medical product labels (way down from 65 changes in February), with changes to the prescribing information to include any of the following areas: boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert, and medication guide.
For a complete detailed accounting of the label changes, please refer to the summary of meds. By clicking onto the drug name, you will be able to view the detailed summary, which will identify the safety labeling section and revised subsection, as well as a brief summary of the new or modified safety information.
The following medications have been affected:
Atacand HCT (candesartan cilextetil/hydrochlorothiazide)
Benicar (olmesartan medoxomil)
Celexa (citalopram hydrobromide)
Janumet (sitagliptin and metformin fixed-dose combination)
Kombiglyze XR (saxagliptin/metformin hydrochloride extended-release)
Lidocaine in 5% Dextrose Injection
Magnevist (brand of gadopentetate dimeglumine)
Reyataz (atazanavir sulfate)
Treximet (sumatriptan and naproxen sodium)
Zometa (zoledronic acid)
Zmax (azithromycin extended release)